Skip to main content

Luminex Racks Up 25th Partnership in Deal with Biosource

NEW YORK, Dec 18 – Luminex said Monday it has signed an agreement with immunoassay maker Biosource International to jointly develop assay and reagent kits using Luminex’s Labmap technology.

Under terms of the agreement, Luminex has received an advance on royalties from the sale of the assays. BioSource, Luminex's 25th partner, will begin marketing the new assay panels using the LabMap technologies beginning early next year.  

The LabMap technology uses microspheres, small lasers, digital processors, and software to perform up to 100 assays per drop of fluid. Biosource is planning to use this technology to develop assays that detect post-translational modification of proteins in order to understand the underlying mechanics of disease processes.   

Biosource will combine this with its signal transduction, cytokine, immunology, and neuroscience kits.

" BioSource's unique assay capabilities in the areas of cytokines, signal transduction and immunology, combined with our proprietary technology, will strengthen both companies' positions in the marketplace,” John Porter, Luminex's director of business development, said in a statement.

 

 

Luminex’ business strategy focuses on developing partnerships with outside companies to commercialize its technology. Bio-Rad, Hitachi, Qiagen, and Upstate Technology have also recently signed on as partners.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.